The BNIP3L Knockout A-549 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human A-549 lung adenocarcinoma epithelial cell line, bearing a targeted disruption of the BNIP3L (NIX) gene. This polyclonal format preserves genetic heterogeneity among knockout alleles, providing a robust experimental tool that more closely mirrors the genetic diversity of tumor cell populations compared to clonal isolates.
The parental A-549 cell line, originally established from a lung adenocarcinoma of a 58-year-old male, serves as a canonical in vitro model for human lung adenocarcinoma research. These adherent epithelial cells retain wild-type p53 and are characterized by their ability to proliferate under atmospheric and hypoxic conditions, making them particularly suited for studying oxygen-dependent signaling pathways. A-549 cells have been extensively employed to dissect mechanisms of apoptosis, autophagy, chemoresistance, and tumor cell adaptation to microenvironmental stresses.
BNIP3L encodes a BH3-only pro-apoptotic protein that integrates stress signals from upstream regulators including HIF-1??, p53, FOXO3a, E2F1, and NF-??B. It localizes to the mitochondrial outer membrane, promoting MOMP and cytochrome c release, which activates caspase-9 and caspase-3 to execute apoptosis. Additionally, BNIP3L mediates mitophagy by binding ATG8 family members LC3A, LC3B, and GABARAP via its LIR motif. It also interacts with anti-apoptotic Bcl-2 and Bcl-xL and cooperates with BNIP3 to balance cell death and survival. Consequently, BNIP3L regulates mitochondrial quality, ROS levels, and cell fate, serving as a key node in HIF-1, autophagy, and apoptosis pathways.
In A-549 lung adenocarcinoma cells, BNIP3L knockout abrogates hypoxia-induced apoptosis and mitophagy, likely enhancing tumor cell survival in low-oxygen conditions. This polyclonal model enables dissection of BNIP3L’s dual roles in cell death and mitochondrial clearance, and assessment of its impact on proliferation, metabolism, and cisplatin resistance. By disrupting the balance between apoptosis and autophagy, BNIP3L deficiency may reveal mechanisms of tumorigenesis and therapeutic vulnerability in lung adenocarcinoma.
These polyclonal BNIP3L knockout cells are suitable for a broad range of experimental approaches: Western blotting and RT-qPCR confirm knockout efficiency; immunofluorescence and LC3 puncta analysis visualize mitophagy; flow cytometry and caspase activity assays quantify apoptosis; mitochondrial membrane potential assays assess organelle health; co-immunoprecipitation probes BNIP3L interactions with Bcl-2, Bcl-xL, or ATG8 members; and drug sensitivity assays evaluate chemoresistance. Hypoxia exposure experiments can further dissect BNIP3L-dependent signaling pathways. For additional product information and technical assistance, please contact Ascent Research.
